Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer

Citation
Jyc. Wong et al., Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer, CLIN CANC R, 5(10), 1999, pp. 3224S-3231S
Citations number
24
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology
Journal title
CLINICAL CANCER RESEARCH
ISSN journal
1078-0432 → ACNP
Volume
5
Issue
10
Year of publication
1999
Supplement
S
Pages
3224S - 3231S
Database
ISI
SICI code
1078-0432(199910)5:10<3224S:ICEEYT>2.0.ZU;2-L
Abstract
cT84.66 is a human/murine IgG(1)with high affinity and specificity for carc inoembryonic antigen (CEA). An earlier Phase I trial defined the maximum to lerated dose for Y-90-diethylenetriaminepentaacetic acid (DTPA)-cT84.66 at 22 mCi/m(2). Dose-limiting toxicities were reversible leukopenia and thromb ocytopenia. The purpose of this Phase I trial was to evaluate the feasibili ty and toxicities of administering higher activities of Y-90-DTPA-cT84.66 w ith stem cell support in patients with CEA-producing breast cancer. Patient s with CEA-producing breast cancer refractory to standard therapies underwe nt peripheral stem cell collection followed by infusion of (111)indium-DTPA -cT84.66. Those patients demonstrating tumor targeting received a single th erapy dose of 90Y-DTPA-cT84.66, followed by Ca-DTPA infusion for 72 h postt herapy. Stem cells were reinfused following a divided schedule. To date, se ven patients have been accrued to this trial. Each patient received an imag ing dose of In-111-cT84.66. Six patients demonstrated tumor imaging and rec eived a single cycle of Y-90-cT84.66 at 15 mCi/m(2) (three patients) and 22 .5 mCi/m(2) (three patients). One patient did not demonstrate tumor imaging and was not treated. At these administered activities, Y-90-cT84.66 was we ll tolerated, No dose-limiting toxicities have been observed. All patients demonstrated hematopoietic recovery after stem cell infusion. One patient d emonstrated stable disease for 4 months; one patient had stable disease and reduction of bone pain for 3 months; and a third patient experienced >50% reduction of an ovarian metastasis, resolution of malignant pleural effusio n, stable pleural metastases, and stable bone scan for 14 months. Prelimina ry results from this ongoing Phase I trial are promising and demonstrate th e feasibility and potential for antitumor effects of stem cell supported Y- 90-cT84.66 therapy in patients with CEA-producing breast cancers.